Skip to content
Screener

IDEAYA Biosciences, Inc. IDYA Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$207.8MBeat by $201.9M
EPS$1.33Beat by $2.28
Revenue estimate$5.9M
EPS estimate-$0.95

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$6.8M
EPS estimate-$1.18

Financials

Q3 2025

Income statement

See full
Revenue$207.8M—
Operating income$108.5M+262%
Net income$119.2M+330%
EPS (diluted)$1.33+322%

Balance sheet

See full
Cash & equivalents$298.9M-25.3%
Total debt$27.2M+45.0%
Total equity$1.1B-7.5%
Total assets$1.2B-4.4%

Cash flow

See full
Operating cash flow$142.2M+389%
CapEx$42.0K-90.8%
Free cash flow$142.2M+386%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.38B-12.7%
Enterprise value$2.11B-10.0%

Returns & leverage

See full
Return on equity-14.1%-3.5pp
Debt / equity0×0.0×
Current ratio12.4×-10.5×

FAQ

When did IDEAYA Biosciences, Inc. report Q3 2025 earnings?
IDEAYA Biosciences, Inc. (IDYA) reported Q3 2025 earnings on November 4, 2025 before market open.
What were IDEAYA Biosciences, Inc.'s Q3 2025 revenue and EPS?
IDEAYA Biosciences, Inc. reported revenue of $207.8M and eps of $1.33 for Q3 2025.
Did IDEAYA Biosciences, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $5.9M by $201.9M. EPS beat the consensus estimate of $-0.95 by $2.28.
Where can I find IDEAYA Biosciences, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-263383) and the 10-Q periodic report (0001193125-25-264632) directly on SEC EDGAR. The filing index links above go to sec.gov.